Metformin monotherapy versus predominantly older non-metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Metformin as a first-line treatment for type 2 diabetes (T2D) is linked to a lower risk of cerebrovascular diseases. This protective effect appears to be dose-dependent, suggesting personalized treatment strategies are crucial.
Area Of Science
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background
- Choosing initial type 2 diabetes (T2D) treatment requires balancing clinical evidence and patient factors.
- Metformin is a common first-line T2D therapy, but its impact on preventing cerebrovascular events needed further investigation.
- This study focused on T2D patients without existing diabetic complications.
Purpose Of The Study
- To evaluate the association between metformin or non-metformin monotherapy and cerebrovascular complications in early-stage T2D.
- To determine if metformin use as initial treatment reduces the risk of cerebrovascular events.
- To explore the dose-dependent effect of metformin on cerebrovascular risk.
Main Methods
- Analysis of 9090 T2D patients without complications, initiated on metformin or non-metformin therapy.
- Propensity score matching was used to ensure comparability between treatment groups.
- Cox regression and competing risk analyses assessed cerebrovascular disease risk, with metformin exposure measured by cumulative defined daily doses.
Main Results
- Metformin users exhibited a significantly lower crude incidence of cerebrovascular diseases (p < .0001).
- Adjusted analyses consistently showed metformin use was associated with reduced risk of overall, severe, and mild cerebrovascular diseases.
- A dose-dependent relationship was observed, with higher metformin doses correlating with lower cerebrovascular risk (incidence rate ratio: 0.62-0.94, p < .0001).
Conclusions
- Metformin monotherapy is associated with a reduced risk of cerebrovascular diseases in early-stage T2D, demonstrating dose-dependent efficacy.
- Potential benefits may be influenced by baseline patient differences and risks associated with alternative medications like sulphonylureas.
- Findings underscore the importance of personalized diabetes management for mitigating cerebrovascular risk in T2D.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...